Kezar Life Sciences, Inc.
Healthcare · EUR · F
Price
€6.202
Cap
€53.86M
Earnings
—
30d Trend
-0.8%
96% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 50×Macro 0.99 (−1%)=50
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Long-term compounder with 29.3% yield
BRAIN47'S ASSESSMENT
I rate Kezar Life Sciences, Inc. at 50/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is quality at 62/100. I classify this as a speculative position with the strongest thesis on a long-term horizon.
PAST PERFORMANCE
1 MONTH
+3.2%
3 MONTHS
-15.8%
12 MONTHS
+86.0%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Long-term compounder with 29.3% yield. Quality (62) and Momentum (58) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 96%. I classify this as a speculative position — elevated volatility at 96% and smaller market cap define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.